Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Socorro Miranda-HernandezAustralian Institute of Tropical Health and Medicine, James Cook University, Townsville and Cairns, Qld, Australia.ORCID http://orcid.org/0009-0004-9527-0034
Manoharan Kumar *Centre for Tropical Bioinformatics and Molecular Biology, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Qld, Australia.ORCID http://orcid.org/0000-0003-4828-2505
Alec Henderson *Australian Institute of Tropical Health and Medicine, James Cook University, Townsville and Cairns, Qld, Australia.
Erin Graham *eResearch Centre, James Cook University, Townsville, Qld, Australia.
Xiao TanInstitute for Molecular Bioscience, The University of Queensland, and QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia.
Jim TaylorCollege of Science and Engineering, James Cook University, Townsville, Qld, Australia.
Michael T MeehanAustralian Institute of Tropical Health and Medicine, James Cook University, Townsville and Cairns, Qld, Australia.
Mario Alberto Flores-ValdezCentro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco (CIATEJ), A.C., Biotecnología Médica y Farmacéutica, Guadalajara, Jal, Mexico.ORCID http://orcid.org/0000-0002-4125-1370
Quan NguyenInstitute for Molecular Bioscience, The University of Queensland, and QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia.ORCID http://orcid.org/0000-0001-7870-5703
Matt A FieldCentre for Tropical Bioinformatics and Molecular Biology, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Qld, Australia.ORCID http://orcid.org/0000-0003-0788-6513
Andreas KupzAustralian Institute of Tropical Health and Medicine, James Cook University, Townsville and Cairns, Qld, Australia. andreas.kupz@jcu.edu.au.ORCID http://orcid.org/0000-0002-9259-7873
Funding
Optimizing vaccine science to improve the outcome of tuberculosis treatmentR01AI161822 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI SUBBIAN, SELVAKUMAR · 2021 to 2025
$3.2M
Department of Health | National Health and Medical Research Council (NHMRC) APP2001262Department of Health | National Health and Medical Research Council (NHMRC) APP2008715Department of Health | National Health and Medical Research Council (NHMRC) APP5121190U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01AI161822
6 · The paper itself
Abstract
About two billion people are latently infected with Mycobacterium tuberculosis (Mtb), which can reside in multiple organs, including the lymphatics. The risk of latent Mtb infection (LTBI) reactivation increases with immunosuppression, such as HIV coinfection, yet the immunological correlates that maintain LTBI remain largely elusive. Using a mouse model of contained lymphatic Mtb infection we dissect the drivers of containment versus reactivation. We show that immunosuppression-induced dissemination of lymphatic Mtb and ensuing progressive disease can be prevented by vaccination with BCG or recombinant BCG even in the absence of CD4
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.